North America Radiotherapy Market Trends, Challenges, and Opportunities

"North America Radiotherapy Market Forecast to 2031" was valued at US$ 3.85 billion in 2023 and is expected to reach US$ 8.46 billion by 2031. It is estimated to register a CAGR of 10.3% from 2023 to 2031. The rising prevalence of cancer, and increasing number of conferences and symposiums to boost awareness about radiation therapy are the key factors driving the market. However, increased risk of adverse effects associated with radiation therapy hamper the market growth.

Rising Prevalence of Cancer Drives North America Radiotherapy Market:

Healthcare facilities across North America are witnessing a substantial increase in the prevalence of cancer, leading to a significant healthcare challenge in the region. A few types of cancer and their prevalence in North America are mentioned below:

Cancer Type: NA Prevalence (2022)

Breast Cancer: 30,6307

Lung Cancer: 25,7284

Prostate Cancer: 25,5782

Brain Cancer: 90,000

As per the above-mentioned figure, breast cancer is one of the most common types of cancer in the US. A report published by Breastcancer.org in January 2022 stated that 1 in 8 women in the nation (or ~13%) will acquire invasive breast cancer over their lifetime. According to the same source, 287,850 new incidences of invasive breast cancer, along with 51,400 new cases of noninvasive (in situ) breast cancer, were detected in women in the US in 2022. In the same year, the country recorded ~2,710 additional cases of invasive breast cancer in men. Approximately 1 in 833 men might develop breast cancer in their lives. With the rise in breast cancer cases, there is an increasing need for effective and targeted therapies to improve patient outcomes.

Aging populations, lifestyle factors such as tobacco use, unhealthy diets, sedentary lifestyles, and environmental exposures to carcinogens are a few factors leading to the rise in cancer cases. With the rise in the number of people being diagnosed with cancer, there is an increasing need for efficient treatment choices such as radiation. Because of its many uses, radiation therapy is a vital component of a comprehensive cancer treatment plan. When surgery is not possible or as effective, radiotherapy might be used as the main treatment for cancer. It can also be administered in conjunction with immunotherapy, chemotherapy, or surgery to improve treatment results. Thus, the rising prevalence of cancer boosts the growth of the North America radiotherapy market.

North America Radiotherapy Market: Regional Overview

Based on geography, the North America radiotherapy market is segmented into US, Canda, and Mexico. In 2023, US held the largest market share. The market growth in the US is driven by the growing digitalization of medical devices, increasing adoption of advanced medical device technologies, growing emphasis on improving treatment outcomes, and rising prevalence of cancer. According to a study published by the American Cancer Society in 2024, approximately 13,820 women in the US were diagnosed with cervical cancer. An increasing number of business activities among market players contribute to the market growth. In November 2020, SOFIE Biosciences, Inc. and Jubilant Radiopharma entered a strategic partnership to expand its US production capacity and distribution channel. Further, in January 2021, Eckert & Ziegler announced its plan to build a cGMP facility for radiopharmaceutical services in the US

North America Radiotherapy Market: Competitive Landscape and Key Developments

Apart from factors driving the market, the North America radiotherapy market report emphasizes prominent players operating in the market; these include Siemens Healthineers AG, Accuray Incorporated, Sumitomo Heavy Industries Ltd, Elekta AB, Hitachi Ltd, Koninklijke Philips NV, Brainlab AG, and PROTOM INTERNATIONAL. Market players focus on expanding and diversifying their businesses and acquiring novel customer bases, which allows them to explore attractive business opportunities prevailing in the North America radiotherapy market. As per company press releases, a few recent developments are as follows: ??

In October 2022, Royal Philips launched two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation. The company’s artificial intelligence (AI) enabled MRCAT Head and Neck radiotherapy application, which allows the use of MR as the sole or primary imaging modality for radiotherapy planning in the treatment of soft tissue tumors in the head and neck, along with the brain, pelvis and prostate, has received FDA 510(k) clearance and is commercially available in the U.S.

In August 2023, Elekta and the IAEA have signed a partnership agreement to jointly pursue common interests, including making advanced cancer treatment available to more patients.

In March 2021, Siemens Healthineers has acquired Varian Medical Systems. Varian Medical Systems with all-cash deal totaling US$16.4 billion. This merger of two leading companies in radiotherapy market is expected to add more advanced radiotherapy products in the market. Both the company's will expand their portfolio in radiotherapy market and gain major market share at global level.

In September 2021, ProTom International, entered into an agreement with the Behnke Group, a Texas-based healthcare consulting firm with decades of experience collaborating with healthcare organizations across the U.S. and internationally. The relationship will enhance ProTom's expansion of U.S. markets through connections with the Behnke Group's network in the industry, allowing a greater number of cancer patients to benefit from ProTom's world-class proton therapy treatments.

In January 2021, Accuray Incorporated has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ClearRT Helical kVCT Imaging for the Radixact System, the next generation TomoTherapy platform. ClearRT is a cutting-edge imaging solution integrated with a powerful, precise, and adaptive delivery platform for radiotherapy

Contact Us: [email protected]